Biomarker driven, agentic AI heart failure system of care
that is scalable to all patients in all care settings
to materially improve patient outcomes.

LifeWave is building a system of care to improve the clinical outcomes of heart failure patients. Empowered by agentic AI, the system enables personalized care and patient self-management that stands to avert hospitalizations and improve healthspan in any setting, especially when cardiology care may not be available.

Among heart failure patients, episodic increases in lung fluid are the number-one factor driving ER visits and hospitalizations. A critical unmet need is identifying these fluid imbalances early, before symptoms, and titrating medication to avert feelings of sickness and hospitalization. Timing the integration of Guideline Directed Medical Therapy (GDMT) at optimized dosages is also a key unmet need affecting patient well being.. 

LifeWave’s patient facing agent and its integral GDMT algorithmic engine, reports diuretic and GDMT recommendations to the patient’s clinician for approval and EHR integration to inform a care plan that will stabilize fluids and optimize GDMT. The agent also facilitates the tracking of key vital signs, alerts, prompts, clinician communications, appointment scheduling, diet and physical activity recommendations, integration with wearables, medication management, HFSA/AHA search, and coordination with the patient’s caregiver agent. The agent is designed with human-centered behavioral intelligence to drive sustained patient self-management and adherence.

Following FDA approval of CardioConnect, LifeWave’s proprietary device for direct lung fluid measurement, the device will be integrated into the agent platform to provide an early-detection “ground-truth” heart failure biomarker – simplifying therapy, patient self-management, clinician management, and improving outcomes.